FindMyKOL

Neil Doherty, MD

Basic profile

Western University of Health Sciences

ORCIDNone on fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionGlendora, CA · WestSpecialtyCardiovascular DiseaseFocusCardiology
Active KOLFindMyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Neil Doherty is a Cardiology physician affiliated with Western University of Health Sciences. OpenAlex indexes 14 publications with 781 citations (h-index 9).

Overview

Scholarship

indexed output and impact (OpenAlex)
14publications

Publications indexed by OpenAlex. Counts exclude supporting files.

781citations

Citations across these publications.

9h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
29companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

29 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Edwards Lifesciences Corporation
    Program year20255 payments
    $144
  • Merck Sharp & Dohme LLC
    Program year20254 payments
    $90
  • Novartis Pharmaceuticals Corporation
    Program year20253 payments
    $82
All 66 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    65.9%
    Statin21.3%
    Atorvastatin Calcium55%Rosuvastatin Calcium22%Simvastatin14%Livalo4%Pravastatin Sodium2%Lovastatin2%
    Part D<11 patients
    Angiotensin receptor blocker (ARB)10.3%
    Losartan Potassium80%Losartan-Hydrochlorothiazide15%Olmesartan Medoxomil6%
    Part D<11 patients

    + 13 more classes in this area

  • Blood & clotting

    23.8%
    Factor Xa inhibitor10.6%
    Eliquis92%Xarelto9%
    Part D<11 patients
    Platelet Aggregation Inhibitor10.1%
    Dipyridamole100%
    Part B, office-administered≥71 patients

    + 2 more classes in this area

  • Metabolism & gastrointestinal

    4.5%
    Potassium supplement1.6%
    Potassium Chloride100%
    Part D≥13 patients
    SGLT2 inhibitor1.1%
    Jardiance100%
    Part D<11 patients

    + 3 more classes in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”